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Abstract
For various types of drug approval processes like INDs, NDAs, ANDAs, veterinary 
drug approval, the data related to bioanalytical method development and validation is 
needed to sponsors. Various agencies namely US FDA, American association of phar-
maceutical scientists (AAPS), Health protection Branch (HPB), Association of ana-
lytical chemists (AOAC), Center for Veterinary Medicine (CVM), U.S. Department 
of Health and Human Services Food and drug Administration, Center for Drug 
Evaluation and Research (CDER), European Medicine Agency (EMA), China Food 
and Drug administration(CFDA), European Bioanalytical Forum (EBF), Global 
CRO council (GCC), ANVISA (Brazil), Japan Bioanalytical Forum (JBF) had done 
collective efforts at different timings to regulate and harmonize bioanalytical method 
development and validation.
Regulatory guidance documents are available as a result of the involvement of 
various official agencies. Bioanalytical method development and validation can 
be performed with various validation parameters by using LC-MS/MS and other 
analytical techniques. Also, there are various stability guidelines and procedures 
were set which are useful for bioanalysis.
The present review is having a special concern on regulatory and practical per-
spectives to researchers for development and validation of the bioanalytical method. 
Keywords: bioanalytical method development and validation, validation parameters, 
sample extraction technique, stability, good laboratory technique, recent trends
1. Introduction and history
When we draw attention on bioanalytical method development and validation, 
from last three decades, there was major progress in this field. Various agencies 
namely US Food and drug administration (US FDA), American association of phar-
maceutical scientists (AAPS), Health protection Branch (HPB), Association of ana-
lytical chemists (AOAC), Center for Veterinary Medicine (CVM), U. S. Department 
of Health and Human Services Food and drug Administration, Center for Drug 
Evaluation and Research (CDER), European Medicine Agency (EMA), China Food 
and Drug Administration (CFDA), European Bioanalytical forum (EBF), Global CRO 
Council (GCC), ANVISA (Brazil) had done collective efforts at different timings 
to regulate and harmonize bioanalytical method development and validation. The 
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very first workshop was held in Arlington, VA, December 3–5, 1990 which was col-
lectively organized by AAPS, U.S. Food and Drug Administration, the International 
Pharmaceutical Federation (FIP), the HPB, and the AOAC and the report of that was 
published in Pharmaceutical research and four other journals. This workshop clearly 
points out two important phases of bioanalytical method development and validation 
that are, an analytical method development in which all parameters of the bioanalyti-
cal method should be developed including assay definition, and actual application 
of a bioanalytical method for Bioavailability, Bioequivalence and Pharmacokinetics 
studies. Draft guidance on bioanalytical methods validation was issued by the FDA 
in January 1999.The second AAPS/FDA bioanalytical workshop was held in January 
2000. The workshop has resulted in a report ‘Bioanalytical method validation—A 
revisit with a Decade of Progress’. This workshop also forms the basis of FDA guid-
ance on bioanalytical method development and validation, in May 2001. A separate 
workshop was held 2000 to discuss validation principles for macromolecules. To 
address the need for guiding principles for the validation of bioanalytical methods for 
macromolecules, the AAPS Ligand—Binding Assay, Bioanalytical focus group devel-
oped and published recommendations for the development and validation of ligand-
binding assays in 2003. Current FDA guidance and bioanalytical methods validation 
workshop white paper was published in 2006. The third AAPS-FDA bioanalytical 
workshop was held on May 1–3, 2006, in Arlington, VA, concluded with several 
recommendations to achieve the above goals and objectives related to bioanalytical 
method development and validation. There was EMA Draft guidance on validation 
of bioanalytical methods held on April 15–16, 2010. GCC, EBF, CFDA, ANVISA had 
taken the wide range of efforts to discuss various practical problems of bioanalysis 
in this decade along with the industry. The regular workshops, conferences of these 
organizations create interest and improve knowledge in bioanalysis field.
In May 2018, U.S. Department of Health and Human Services, Food and drug 
administration, Center for Drug Evaluation and Research (CDER) and Center 
for Veterinary Medicine (CVM) were published guidance for industry regarding 
bioanalytical method development and validation [1].
2. Need of bioanalytical method development and validation
Sponsors are applying for investigational new drug application (IND), new drug 
application (NDA), Abbreviated new drug application (ANDA) to FDA. To fulfill 
the formalities, they have to submit human clinical pharmacology, bioavailability 
(BA), and bioequivalence (BE) studies, requiring pharmacokinetic (PK) evaluation 
including non-human pharmacology and toxicology studies and preclinical stud-
ies, for this purpose there is a need to develop and validate bioanalytical method. 
Generally, for industrial use, the bioanalytical methods are developed in biological 
matrices such as blood, serum, plasma, or urine [2]. The new guidance was having 
influence of chromatographic assays (CCs) and ligand binding assays (LBAs), as 
these types of assays can quantitatively determine the drugs and their metabolites, 
therapeutic proteins and biomarkers in biological matrices such as blood, serum, 
plasma, urine and tissues. The guidance document also includes the public com-
ments on the revised draft published in 2013. It also provides recommendations 
for the development, validation and in-study use of bioanalytical methods. The 
recommendations can be modified with proper supporting documents according to 
the specific type of bioanalytical method. The advances in scientific and technical 
factors were included in the guidance. For the successful conduct of nonclinical, 
biopharmaceutics and clinical studies, the validated analytical methods which 
provide quantitative data of analytes including drugs and biological products and 
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biomarkers in given biological matrix are critical ones. These validated methods 
provide important data related to safety and effectiveness of drugs and biological 
products. The validated method addresses the key questions related to specificity, 
accuracy and precision, sensitivity, sample collection, handling, storage of analyte. 
There is need for partial or cross validation when there are changes to a validated 
method. The level of validation should be proper for intended purpose of the study 
which is stated by fit-for-purpose. The most crucial studies submitted in an NDA, 
BLA or ANDA which helps in regulatory decision making for approval, safety such 
as BE or pharmacokinetic studies should contain validated bioanalytical methods. 
The analytical laboratory, which is involved in conducting toxicology studies for 
regulatory submissions, should follow 21 CFR 58 and GLP [2].
3.  Instrumentation for bioanalytical method development and 
validation
Gas chromatography, high-pressure liquid chromatography, LC and GC, 
combined with mass spectrometric (MS) procedures such as LC-MS, LC-MS-MS, 
GC-MS, and GC-MS-MS are used for quantitative analysis. For the quantifica-
tion of conventional, low molecular weight drugs in biological fluids has shifted 
dramatically in favor of mass spectrometry-based methods, particularly LC-MS 
and LC-MS-MS. In the years of 90’s there have been tremendous advancements in 
the field of mass spectrometry with the development of new interfaces, ionization 
and detection techniques. These advancements resulted in the rapid emergence and 
widespread commercial use of hyphenated mass spectrometry-based assays, which 
have largely replaced conventional HPLC, GC, and GC-MS assays [2].
4. Validation and acceptance criteria
4.1 Background
The main purpose of bioanalytical method development is to clearly define 
the design, operating conditions, limitations and suitability of the method for 
its intended purpose. It also ensures that the method is optimized for validation. 
Before starting development of bioanalytical method, the sponsor should perform 
the detail study of analyte including physicochemical properties, in vitro and 
in vivo metabolism and protein binding etc.
The procedures related to extracting the analyte from biological matrix and its 
detection are the important tasks in method development.
Following are the parameters for method development:
• Reference standards
• Critical reagents
• Calibration curve
• Quality control samples(QCs)
• Selectivity and specificity
• Sensitivity
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• Accuracy
• Precision
• Recovery
• Stability of the analyte in the matrix
The developed method should be suitable for analysis of study sample and that 
is proved on the basis of bioanalytical method validation results. In case if there is 
new drug entity, its metabolites or biomarkers or any revisions to existing method, 
the full validation is necessary. The detailed written description like protocol, SOP’s 
should be established. The detailed description of parameters, environment, matrix, 
collection of sample should be included. Any parameter and results draws any 
conclusion should be documented and presented in detailed report. Each analyte 
should be validated in biological matrix [1].
Three types of validation are full validation, partial validation, cross valida-
tion. When there is completely new drug entity under investigation, bioanalytical 
method is developing for the very first time, any small change in laboratories, 
instrument, software, matrix, (from rat plasma to mouse plasma or matrix 
within species like human plasma to human urine) in that case validation can 
range from as little as one assay accuracy and precision determination to a 
nearly, full validation. In Cross validation, comparison is done in between two 
bioanalytical methods. For example, data generated using different analytical 
techniques like LC-MS-MS vs. ELISA in different studies are included in a regula-
tory submission [3, 4].
4.1.1 Validation parameters
According to FDA guidance following are common method validation terms.
4.1.1.1 Reference standards and critical reagents
The reference standard should be authenticated with known identity and purity 
to prepare the known concentrations. The reference standard should be identical 
to the analyte under study but if not possible then the established chemical form 
like free base, free acid or salt with known purity can be used. For commercially 
available reference standards, they should be with certificate of analyses (CoA) as 
per requirement of USP standards. In certain cases, if there is no CoA for internally 
or externally generated standards, then detail information and evidences regarding 
purity, source, and lot number should be provided. If expired reference standards 
are available in that case CoA is necessary or there should be regeneration of iden-
tity and purity standards. In case of internal standards, there is no need of CoA, if it 
is not interfering with analyte. The critical regents should be properly characterized 
and documented for identity, purity and stability. These critical reagents include 
antibiotics, labeled analytes and matrices.
In case there is change in critical reagent like lot-to-lot change or switches to 
another reagent then there is need of assay validation [1].
4.1.1.2 Calibration curve
The proper quantitation range should be selected for assay and calibration 
standards based on expected concentration range in the particular type of 
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study. While studying Ligand Binding Assays (LBAs) there should be anchor 
points outside the range of quantification in addition to calibration standards. 
However, these anchor points should not be the part of the acceptance criteria. 
In most of the LBAs the calibration curves are nonlinear therefore more calibra-
tion standards are needed to finalize the calibration range for LBAs than for 
Chromatographic assays (CCs).
The response-error relationship for LBA standard curves is variable func-
tion of the mean response. The concentration-response relationship should 
be explained with simple model including weighting scheme and regression 
equation. The reproducible calibration curve should be obtained. The biologi-
cal matrix should be same throughout the study. The calibration curve should 
be generated for each analyte if sample contains more than one analyte. In case 
of surrogate matrices, there should be proper justification and validation of the 
calibration curves [1].
4.1.1.3 Quality control samples
For determining precision and accuracy as well as stability, the quality control 
samples should be used. During method development stage, freshly prepared QCs 
are recommended. For evaluation of performance of method and stability of ana-
lyte, QCs are helpful. While determining the precision and accuracy of the method, 
the performance QCs are included. The stability QCs are useful to determine stabil-
ity under stress condition. The calibration standards and QCs are prepared from 
separately. The calibrators and QCs should be prepared in lots of blank matrix that 
is free of interference or matrix effects [1].
4.1.1.4 Accuracy
The degree of closeness of the observed concentration to the nominal or known 
true concentration. It is typically measured as relative error (% RE) [5, 6].
4.1.1.5 Precision
Measurement of scattering for the concentrations obtained for the replicate 
sampling of a homogeneous sample. It is typically measured as coefficient of variation 
(%CV) [5, 6].
4.1.1.6 Selectivity
The ability of the bioanalytical method to measure and differentiate the analyte 
in the presence of components that may be expected to be present. These could 
include metabolites, impurities, degradants or matrix components [5, 6].
4.1.1.7 Sensitivity (LLOQ , Lower limit of quantitation)
The lowest concentration of an analyte in a sample that can be quantitatively 
determined with an acceptable precision and accuracy [5, 6].
4.1.1.8 Standard curve
The relationship between the experimental response value and the analytical 
concentration [5, 6].
Recent Advances in Analytical Chemistry
6
4.1.1.9 Linearity
The ability of the bioanalytical procedure to obtain test results that are directly 
proportional to the concentration of an analyte in the sample within the range of 
the standard curve [5, 6].
4.1.1.10 Quantification range
The range of concentration, including the LLOQ and ULOQ (Upper limit of 
Quantitation) that can be reliably and reproducibly quantified with suitable accu-
racy and precision by a concentration-response relationship [5, 6].
4.1.1.11 Recovery
The extraction efficiency of an analytical process, reported as a percentage of 
the known amount of an analyte carried through the sample extraction and pro-
cessing steps of the method [5, 6].
4.1.1.12 Matrix factor
A quantitative measure of the matrix effects due to suppression or enhancement 
of ionization in a mass spectrometric detector [5, 6].
4.1.1.13 Stability
The chemical or physical stability of an analyte in a given matrix under specific 
conditions for given time intervals [5, 6].
4.1.1.14 Reproducibility
Ability of the method to yield similar concentration for a sample when measured 
on different occasions [5, 6].
4.1.2 Stability study
Special focus is given on stability study. Various stability parameters can be 
explained as below [5, 6].
4.1.2.1 Stock solution stability
The stock solution stability of drug sample and internal standard should be 
evaluated at room temperature for minimum of 6 h. The stock solutions are kept 
at frozen or refrigerated over the period. Then these stock solutions are evalu-
ated by comparing with the response of freshly prepared stock solutions. The 
stock solution stability should be performed at least for one concentration in 
duplicate.
4.1.2.2 Post preparative (extracted samples or autosampler tray) stability
This stability is determined for extracted samples. To cover expected run time 
for the analytical batch and to allow delayed injection due to some instrument 
malfunctioning or long term storage of the samples, this stability is determined for 
7Bioanalytical Method Development and Validation: A Review
DOI: http://dx.doi.org/10.5772/intechopen.81620
~48 to 96 h. This stability is determined on QC samples which are kept for measur-
able time at the autosampler tray. These samples are analyzed with fresh standards.
4.1.2.3 Benchtop stability
The QC samples at minimum of two concentration levels are kept at room tem-
perature for 4–24 h. It covers the time to extract the samples. The concentrations 
are analyzed by comparing with their nominal values. The samples are analyzed in 
replicates generally in triplicate.
4.1.2.4 Freeze-thaw stability
This stability is determined at a minimum of two concentration levels. The 
samples are frozen overnight for −20 or −70°C. Then it is removed and thawed at 
room temperature. After that, the samples are frozen again at the same temperature 
for 12–24 h and again thawed. This freeze thaw cycle is repeated for two more times. 
After completion of third cycle the samples are analyzed. If more degradation is 
observed than normal values then the first and second freeze-thaw cycle is repeated 
and the step in which instability occurred is determined. The freeze-thaw cycle can 
be extended as per requirement.
4.1.2.5 Freezer storage stability
The freezer storage stability should be carried out at nominal freezer storage 
temperature during the validation process. The long term stability should be carried 
out and properly documented as per the procedure discussed below.
4.1.2.6 Postvalidation long-term stability
This stability is performed after validation. The two QC samples in the matrix 
low and high concentration level are analyzed by keeping at long-term storage 
temperature and analyzed in triplicate. The postvalidation long-term stability 
should be performed in regular intervals starting from 1, 3, 6, 9 and 12 months 
in accordance with the length of stability required. The long-term stability of 
incurred samples at storage data should be assessed with stored in vivo samples. 
The results should be incorporated in the original report or separate report should 
be prepared.
4.1.2.7 Matrix stability
At lower temperature, there may be denaturation of matrix proteins. Therefore 
matrix stability should be validated. For that purpose, additional stability should be 
carried out at lower temperatures for sample matrix [7].
4.1.2.8 Bioanalysis of hemolyzed samples
As per 2009 EMA draft guidance and the 2003 ANVISA guideline hemolyzed 
samples should be analyzed during method validation but practically that will dif-
ficult at the time of method validation, therefore, it was recommended to perform 
at the time of method development. Data reliability and reproducibility should be 
monitored according to an internal standard (IS) and incurred sample reproduc-
ibility (ISR) response. Also one can apply standard addition or standard dilution for 
further investigation of data reporting. However, the final recommendation about 
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hemolyzed sample is that there is no standard approach for testing of these types of 
samples, so there should be the least impact on method development or validation.
4.1.2.9 Whole blood stability evaluation
The immediate spinning down of aliquot of whole blood containing the drug 
taken immediately following preparation (time zero) followed by the spinning down 
of another aliquot following the stability period. The whole blood stability should be 
performed during method validation. However, there are various approaches for deter-
mination of whole blood stability. In case of large molecule, it is not applicable [7].
4.1.2.10 Dilution effects
The integrity of the dilution should be monitored during validation by QC 
samples above the ULOQ with like matrix to bring to within quantitation range, if 
the method measures the diluted samples. There should be proper demonstration of 
accuracy and precision of these diluted QCs [1].
5. Sample collection, stability, storage, sample transport
For analysis purpose, some processing is required after collection from an animal 
or human subject. Harvesting of plasma or serum can be done by centrifugation 
process and it is kept in frozen condition. The conditions like temperature, centrifu-
gation time and force, maximum from sampling to freezing sample are specified 
and maintained for proper development of the method. If an analyte is less stable in 
whole blood than plasma, any delay in processing the sample or poor temperature 
control could result in analyte loss; in such case, one can apply stabilizers or other 
special sample handling conditions. The stability of analyte in biomatrix should be 
defined during validation and analyzed during that period only. To obtain Short-
term stability, freeze-thaw stability, long-term stability in bio-matrix (typically 
at −20 or −70°C), there is need to maintain all parameters like backup capacity of 
freezer, alarm system for staff, freezer and also all related document, to track sample 
during collection, storage and stability. Bio-matrix samples are usually frozen in 
insulated containers with dry ice. The main concern is ensuring that the shipment is 
still frozen upon arrival. Shipments are usually packed with sufficient dry ice to last 
for a significantly greater period than the anticipated shipment time. Samples are 
split into two aliquots at the collection site, for additional security; a set of reserve 
aliquots can then be safely stored until the first set is received for analysis [8–14].
6. Sample extraction techniques
Sample preparation is most important and critical step in bioanalytical method 
development and validation. The main task is to remove interferences present in 
the sample and to make the sample with the higher concentration of analyte, which 
contributes to the sensitivity of the method [6].
There are various methods of extraction as follows.
6.1 Liquid-liquid extraction
In liquid-liquid extraction, the analyte gets partitioned in between two immis-
cible phases. Generally, selective partitioning of an analyte of interest is occurring 
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in between two immiscible solvents and proper extracting solvents plays important 
role in this step. In LLE, the analyte gets distributed in one immiscible phase and 
this partitioning also helps to separate interferences. The analyte is dissolved in a 
suitable solvent. Then the second solvent is added which should be immiscible with 
the first solvent. The contents in the sample tube are mixed thoroughly and the two 
immiscible solvents are allowed to separate into two layers. The less dense solvent 
will be upper layer, while the more dense solvent will be the lower layer. The analyte 
mixture will be get separated or distribute in two immiscible solvents according 
to their partition coefficient. The extent of partition of analyte is depends upon 
the solubility characteristics of the components of analyte in mixture. As there is 
the partitioning of analyte in between two immiscible layers, the analyte which is 
soluble in less dense solvent will be at the upper layer and which one more soluble 
in the denser solvent will be in the lower layer. These two immiscible layers are 
separated and after separation, the respective analyte is isolated. The hydrophilic 
compounds are getting soluble in polar aqueous phase and hydrophobic compounds 
are in the organic solvent. Generally, by evaporation, the analyte in the organic 
phase is recovered and diluted with mobile phase and then injected into the column 
while aqueous phase may directly be injected [6].
In LLE analyte is brought in the organic phase, and for that, the required condi-
tions are maintained. In this, there is a direct extraction of biological material with 
the water-immiscible solvent. The important task is partitioning of analyte in to the 
organic phase in which aqueous phase is also present [7].
6.2 Solid phase extraction
In Solid Phase Extraction, the partitioning is occurring in between liquid and 
solid phase. The main advantage of SPE is removing impurities present in analyte, 
which helps in increasing the sensitivity of the method. The removal of particulate 
matter from analyte is major output of SPE. In SPE, multiple sampling generally 
12–24 with a lower quantity of solvent with automation are major contributing 
factors. In SPE the recovery of the sample is higher. Small disposable column or car-
tridge is employed for partitioning. The SPE consists of the medical syringe which 
is packed with 0.1–0.5 g of sorbent generally C18 silica. Liquid samples are added 
to the cartridge and wash solvent is selected to either strongly retain or unretain the 
analyte. To minimize the presence of interferences, this method is advantageous. 
Even though analyte get retained on the cartridge, the interferences can be eluted 
or washed, that results in the analyte-free from interferences. Then the analyte is 
eluted with elution solvent and either directly injected in or evaporated to dryness 
followed by dilution with the HPLC mobile phase [15, 16].
6.3 Protein precipitation
Protein precipitation is one of the methods to make the matrix interference free. 
This can be achieved by denaturation and precipitation. Trichloroacetic acid and 
perchloric acid has a wide choice as a precipitating agent. Various organic solvents 
like methanol, acetonitrile, acetone, and ethanol are the wide choice for removing 
plasma proteins and possess compatibility with high performance liquid chroma-
tography (HPLC) as a mobile phase. One part of sample matrix is diluted with 
three–four parts of the precipitating agent then vortex mixing is carried out. After 
that centrifugation, filtration is done to remove the protein mass. The supernatant 
liquid or filtrate obtained is directly analyzed for the analyte of interest. For quan-
titative analysis, the supernatant can be isolated, evaporated to dryness and then 
reconstituted with a suitable solvent before analysis [8]. In protein precipitation 
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method, the analyte should be freely soluble into the reconstituting solvent. Either 
by converting soluble protein to a nonsoluble state that salting out or by the addi-
tion of water miscible precipitation solvent or organic solvents such as acetone, 
ethanol, acetonitrile or methanol, this technique can be achieved [10, 15].
6.4 Solid phase microextraction
Solid Phase Microextraction involves the sampling, extraction, concentration 
and sample introduction single step which is solvent-free step. The bonded phase 
which is fused silica fiber coated with polyacrylate, polydimethylsiloxane, carbowax 
is kept in contact with the sample and exposed to the vapor, also it can be placed in 
the stream of a gaseous sample to isolate the analyte and concentrate analyte into a 
range of coating materials. Lastly, the fibers are transferred to analytical instruments 
like gas chromatography (GC) and GC/mass spectrometry (GC/MS) for separation 
and quantification of the target analyte with the help of syringe. For routine analysis 
of volatile and semi-volatile compounds, SPME can be implemented. Exposed fiber 
has the ability to extract and sample delivery is a key aspect of this method [8–14]. 
The SPME apparatus is a very simple device. It looks like modified syringe consisting 
of a fiber holder and a fiber assembly, the latter containing a 1–2 cm long retract-
able SPME fiber. Analyte in the sample is directly extracted and concentrated to 
the extraction fiber. The method saves preparation time and disposal costs and can 
improve detection limits. SPME was also introduced for direct coupling with high-
performance liquid chromatography (HPLC) and HPLC-MS in order to analyze 
weakly volatile or thermally labile compounds not amenable to GC or GC-MS [12].
6.5 Matrix solid-phase dispersion
In Matrix solid-phase dispersion technique solid matrices are used for sample 
preparation. It is advantageous as the sample requirement is less that is 1 g with 
low solvent, which is why it is also termed as microscale extraction technique. Near 
about 98% solvent use is reduced and giving 90% sample turnaround time. In the 
Conventional extraction of an organic analyte from tissue, the homogenization 
of small amount of sample tissue with bulk bonded silica-based sorbent has to 
perform, this can be achieved in mortar and pestle. The structure of tissue is getting 
disturbed due to mechanical shearing. The sample gets dispersed on the surface 
of support sorbent, for this, hydrophilic and hydrophobic interaction plays a role 
which causes the mixture to become semi-dry and free-flowing homogeneous blend 
of the sample. The sample disruption will be performed due to bound solvent in 
the sorbent. The sample disperses over the surface of the bonded phase support 
material to provide a new mixed-phase for isolating analytes from various sample 
matrices. The interferences and analyte are eluted by transferring in to a pre-fitted 
SPE cartridge. This technique has recently been applied, using acid alumina, to 
extract the organic analyte. The two important lacunas with the method are longer 
analytical time and having a limited limit of determination (LOD) [15, 20, 21].
6.6 Supercritical fluid extraction
Supercritical fluid extraction is generally used for removing nonpolar to moder-
ately polar analyte from the matrix. As per regulatory point of view, there should be 
need to replace organic solvents and it is advantageous in the sense of environment. 
The density of the supercritical fluid is like liquid while its viscosity and diffusivity 
is in the gas and liquid values. By reducing the pressure and by the evaporation, the 
recovery of supercritical solvent can be obtained. Even though there is increase in the 
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pressure, if the temperature is maintained above the critical temperature, the liquid 
phase will not be appeared. To obtain more efficient extraction the density of super-
critical fluid should be like liquid which can be obtained by increasing pressure and 
this step is more advantageous that of organic solvents. Carbon dioxide dissolves many 
volatile polar compounds, acting good supercritical solvent. This work can be achieved 
in the presence of trace amounts of polar co-solvents like water and short-chain alco-
hols. Supercritical fluids can be used to extract analyte from samples [15, 17]. The SFE 
is fast process. The rate of diffusion of a species in the fluid and viscosity of the fluid 
determines the rate of mass transfer between a sample matrix and an extraction fluid. 
The greater the diffusion rate and the lower the viscosity, the greater will be the rate of 
mass transfer. The SFE can generally be completed in 10–60 min. The solvent strength 
of a supercritical fluid can be varied by changes in the pressure and to a lesser extent in 
temperature. Many supercritical fluids are gasses at ambient conditions. Thus recovery 
of analyte becomes simple compared to organic liquids. Some supercritical fluids are 
cheap, inert and nontoxic. Thus they are readily disposed-off after an extraction is 
completed by allowing them to evaporate in to the atmosphere [11].
6.7 Column switching
The broad definition of 2D (or multidimensional) chromatography is a ‘Selective 
transfer of analyte of interest from a first column to the second column. (By means of 
switching valve)’ [12]. Column switching is one of the interesting techniques for sam-
ple preparation. In this technique, the analyte of interest is retained and separated 
on HPLC stationary phase while the unretained components are eliminated from the 
column. In this technique, the component of interest separated at lower retention 
time is cut and transferred onto another HPLC column for further separation. The 
important advantage is that the process is automated and whatever transfer of analyte 
occurs can be determined quantitatively. The analyte gets transferred quantitatively 
without any loss in concern with the adsorption or degradation [15, 18, 19].
7. Acceptance criteria for method validation
One care must be taken while preparing standard and QC samples, which they 
should be prepared from same stock solution, also the stability and accuracy of both 
should be verified before proceeding for actual practical. The selectivity of sample 
matrix should be verified, can be used throughout the experiment. Standard curve 
samples can be inserted at any sight in the run.
7.1 Matrix-based standard calibration samples
75% or a minimum of 6 standards, when back-calculated(including ULOQ ) 
should fall within ±15% of nominal, except for LLOQ when it should be within 
±20% of the nominal value.
7.2 Quality-control samples
At least five replicates, at a minimum of three concentration levels that are 
LLOQ , MQC and HQC should be inserted in into each run. The results obtained for 
QC samples are the basis of acceptance or rejection of the run. At least 67% (4/6) 
of the QC samples must be within 15% of their respective nominal (theoretical) 
values; 33% of the QC samples (not all replicates at the same concentration) may be 
outside the ±15% of the nominal value [3].
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7.3 Selectivity
For chromatographic assays, the peak response in the blank matrix at the reten-
tion time of analyte(s) should be no more than 20% of the response for the lower 
limit of quantitation (LLOQ ) sample [5, 6].
7.4 Sensitivity
Sensitivity of the method is defined as the lowest concentration that can be 
measured with an acceptable limit of accuracy and precision. By analyzing at least 
five replicates of the sample at the LLOQ on one of the validation days should be 
performed for determining the accuracy and precision. The samples used should 
be different from that of calibration curve samples. The accuracy as determined by 
the relative error (RE %) at this concentration should be within ±20% and the CV 
should be less than 20% [5, 6].
7.5 Accuracy and precision
Accuracy and precision should be determined for both intra-and inter-runs. 
They are determined at three concentration levels, which are representing entire 
calibration range. The mean and CV of observed QC concentrations should be 
determined to obtain intra-run accuracy and precision. The mean of the observed 
concentrations should be within ±15% of the nominal at all concentrations of the 
QC samples. Coefficients of variation (indicating precision) around the mean 
observed concentration should not exceed 15% at all concentrations. For both intra 
and inter-run, all QC samples should be considered for calculation including the 
samples that are failed [5, 6].
7.6 Extraction efficiency
The ratio of the results obtained for analyte from an extracted sample to the 
results obtained by analyzing unextracted samples. In both cases samples should 
contain same amount of analyte. The extraction efficiency need not be very high, 
but it should be consistent, precise and reproducible. One can also determine the 
extraction efficiency of IS. The ratio of the extraction efficiencies of the analyte and 
IS provide an IS-normalized extraction efficiency [5, 6].
7.7 Matrix effect
The Matrix effect is the suppression or enhancement of ionization of analyte 
by the presence of matrix components in the biological samples. The quantitative 
measure of matrix effect is matrix factor. Matrix factor = peak response in pres-
ence of matrix ions/peak response in absence of matrix ions [22]. For determining 
matrix effect standard curve should be compared with the standard in the buffer 
to detect matrix effects. Parallelism of diluted study samples should be evaluated 
with the diluted standard to detect matrix effects [9]. Due to disease conditions, 
there may be variations in lipid or specific or total protein that should be consid-
ered while determining matrix effect. During method development, the impact 
of hemolyzed and lipemic samples may be assessed. At the time of validation, 
suppression/enhancement (matrix effect), should be assessed instead of matrix 
factor [21].
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7.8 Recovery
The recovery of analyte should be consistent and reproducible. It is not expected 
that it should be 100%.The recovery should be determined at three concentrations 
that are low, medium, and high by comparing analyte results of extracted samples 
with those of spiked control extracts [21].
8. Good laboratory practices: an important part of regulatory acceptance
The workshop on EMA draft guideline on validation of bioanalytical methods 
held on April 15–16, 2010 in Brussels that was jointly organized by the European 
bioanalysis forum (EBF) and the European federation of pharmaceutical Sciences 
(EUFEPS). The draft guideline explains how Good Laboratory Practices are 
essential for bioanalytical method development and validation. For regulatory 
acceptance of method, the GLP should be followed. The word that is “regulated 
bioanalysis” should be implemented while practicing the bioanalysis. The internal 
quality assurance units are responsible for proper procedures, documentation of 
data and review of all processes. This should be performed in a transparent environ-
ment. In addition, the fundamentals’ of GLP should be strictly and interestingly 
supported by both bioanalytical chemist and regulators that contribute in the reli-
ability of bioanalytical results. When there is any new or literature based method, 
complete validation should be performed. In case there is a change in the matrix, 
partial validation should be performed. For QC samples, which are separated in two 
aliquots in such case, cross validation is to perform. Selectivity should be confirmed 
by using at least six sources of the appropriate blank matrix. In the case of matrix 
effect at three times LLOQ and additional determinations of at medium and high 
QC were recommended. Stability should be performed at every stage. The between-
run accuracy of QC samples should be within 15% of the nominal value and 
between-run precision should not exceed 15% [8]. SOPs should be readily available 
for various activities of bioanalytical method development and validation. Study 
director or principal investigator should have overall responsibility of the bioana-
lytical method. In addition, all protocols should be generated according to GLP and 
any alteration in protocol can be done by issuing amendment [8–14].
9. Recent trends of bioanalytical method development and validation
As per second China bioanalysis forum (CBF), all approved clinical trials that 
are BE and pharmacokinetic (phase I–IV trials) should be registered and published 
on CFDA website eng.sfda.gov.cn. CBF expert committee (EC) participated in the 
first independent BMV draft guidance of the Chinese pharmacopeia [14].
European bioanalytical forum was established in 2006 to focus on the issues on 
ISR, matrix suppression and metabolite quantification. The EBF-IGM also focuses 
on Ligand-binding assays (LBAs) and immunogenicity assessment. There were 
certain observations of the industry as well as FDA during audits creates interest 
in ISR (Incurred sample reproducibility).It should be included in bioanalytical 
support. Because there were, different observations and readings were found while 
performing repeat analysis. In bioanalytical method validation, human methods 
are considered validated without ever applying to study samples which are the 
major drawback of FDAs guidance. The EBF provides additional clarification and 
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recommendations with a view to achieving uniformity in quantitative bioanalytical 
estimations of various molecules. The ISR reinforces confidence that a method is 
valid and reproducible. The few important recommendations related to acceptance 
of ISR suggest that it does not accept or reject a study. Failed ISR should lead to 
investigation and follow-up. For small molecules, two-thirds of repeats agree within 
20%, large molecules within 30%.Incurred sample reproducibility enforces the con-
fidence that a method is valid and reproducible for intended purpose. ISR should be 
part of method validation in addition to various parameters. It is important to docu-
ment of robustness and repeatability of the method. It is part of regular process 
check on laboratory procedures like SOPs and analysis protocols. Whenever the first 
time in a new matrix whether animal or human, in new population, first patient 
study, disease state changes in patient population, any major method change, 
existing method in new laboratory, whenever scientific reasons require retesting of 
ISR, process check, all BE studies, incidental check in any studies collectively both 
clinical and nonclinical studies, there is recommendation of ISR by EBF [23].
The 5th Global CRO Council was held on 13 November 2011 in which European 
medicines Agency (EMA) guidelines were the main issue of discussion. The GCC 
recommends three major recommendations on incurred sample reproducibility, 
consultants, and good clinical practice. The ISR should be carried out in separate 
batches from that of study samples in a very short period finalized on the priority 
basis of knowledge related to the stability of the analyte and the matrix. The mean 
of two results that are of original and ISR results and their difference should be 
determined. They also recommend good clinical practices with respect to method 
validation, ISR, repeat analysis, Data recording, reporting and retention of data, 
facilities and equipment maintenance, computerized systems, QA and QC, SOPs 
and policies [24]. The European medicine agency (EMA) suggests about the stabil-
ity of sample in the matrix containing all the analyte. Accordingly, Global CRO 
council recommends stability validation experiments in presence of co-admin-
istered compounds for fixed-dose drug combination studies including patient 
studies [25]. The 2nd Global CRO Council (GCC) for bioanalysis closed forum was 
held on 15 April 2011 in Montreal, Canada. In this forum they have suggested 10 
recommendations on internal standard response, analyte stability, stability of light-
sensitive compounds, Incurred sample reanalysis, incurred sample accuracy, whole 
blood stability evaluation, stability of the Co-administered compounds, rejected 
evaluations of validation reports, stock solutions used for calibrates and quality 
control sample preparation, carryover control, which are essential while develop-
ing bioanalytical method [26]. The GCC also recommends 20 recommendations 
on new EMA guidelines on issues like certificate of analysis, internal standard, 
calibration curve, accuracy, stability, sample stability, matrix effect, presence of 
excipients, matrix obtained from special populations, study samples, calibration 
standard and QC samples, acceptance criteria, chromatogram integration, sample 
reanalysis, reference standards, matrix effect, matrix selection, parallelism, stabil-
ity, reagents [27].
The 5th Workshop on Recent Issues in Bioanalysis(WRIB) was held in Montreal, 
Canada, on 13 and 14 April 2011 which was organized by Calibration and Validation 
Group (CVG).This workshop gives 17 recommendations on various points like alter-
nate detectors, tissue analysis, whole-blood stability evaluation, chromatographic 
peak integration, Systems cross-validation, stability issues in bioanalytical method 
validation and the definition of fresh, fit-for—purpose validations, interpretation 
of guidelines between different auditors, batch failure, effect of anticoagulant 
counter ions, differences in slopes of the calibration curves on different LC-MS/
MS systems, variability of the IS response in analytical results, reinjection versus 
reanalysis versus nonreportable values, matrix stability for co-formulated and 
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co-administered drugs, Hemolysis of samples, method transfers and cross-valida-
tions, method development data. These recommendations should be studied and 
implemented for proper regulatory acceptance of bioanalytical methods [28]. The 
new draft guidance ANVISA (Brazil) was put forth in 2011. Japan bioanalysis forum 
(JBF) was also put forth in 2011, which has participated for MHLW bioanalytical 
study group to draft Japanese guidelines for bioanalytical method development. 
Both ANVISA and JBF guidelines are having the impact of EMA guidelines with no 
any remarkable difference [29]. In September 2013, FDA released a draft guidance, 
which includes number of changes in bioanalysis and addition of biomarker assays 
[30]. In December 2013 there was 8th GCC closed forum to discuss 2013 revised 
FDA draft guidance. It was recommended that there should be minimum require-
ments for biomarker assays. It should be extended to validated, qualified or screen-
ing assays. In case of full validation, the pharmacokinetic assay approach can be 
implemented but there will be certain limitations as biomarker kit are involved [31].
10. Conclusion
To evaluate and interpret bioavailability, bioequivalence, pharmacokinetic and 
toxicokinetic study data, bioanalytical method validation plays an important role. 
In this, the quantitative estimation of drug and its metabolites in the biological fluid 
can be performed. There is a need to discuss issues related to bioanalytical method 
development and validation and need to follow the guidelines, regulatory aspects 
that are formed during the tenure of last three decades. Nowadays LC-MS/MS plays 
important role in developing bioanalytical methods including GC-MS and other 
techniques which are useful for these types of tasks. Various related authorities are 
having a keen focus on different aspects of bioanalytical method development and 
validation. If researchers applied all practical aspects of bioanalytical method devel-
opment and validation for determination of API or certain chemical entity, that 
is advantageous for regulatory submissions of particular drug component. While 
developing the bioanalytical method there should be complete clarity about the 
nature of the analyte, that whether it is a small molecule or macromolecule. There 
certain differences in principles of bioanalysis for these types of an analyte. For 
small molecules generally LC-MS and for macromolecules, Ligand-binding assays 
should be performed. Recent trends related to bioanalytical method development 
and validation should be followed with GLP requirements for regulatory acceptance 
of method. There are continuous conferences; workshops are arranged at different 
sights of the world by CBF, GCC, and other related agencies to discuss, to solve and 
to improve practical difficulties and additions in the field of bioanalysis.
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